glp 1 agonists alzheimer's Antidiabetic GLP-1 Receptor Have Neuroprotective Properties in Experimental Animal Models of Disease PDF] Novel dual GLP-1/GIP receptor

Other findings included: Gallbladder issues (especially with rapid weight loss) Pancreatitis (rare, with unclear causality) Thyroid C-cell hyperplasia (in animals, not seen in humans) Lean mass lossup to 40% of weight lost may be muscle in older adults None of these derailed regulatory approvals

Conclusions and Relevance GLP-1 RA therapy in IIH is associated with significant reductions in medication use, symptoms/signs, and procedural interventions, suggesting its potential as a management strategy

has held lectures for Astrazeneca, Sanofi, NovoNordisk, and MSD

Significant data emerged in this regard from the previously discussed trial by Armstrong et al

Drug development for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), has been surprisingly challenging 1